Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia

Ilaria Schiavetto, Paolo Pedrazzoli, Vera Basilico, Salvatore Siena

Research output: Contribution to journalArticle


Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis- stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue.

Original languageEnglish
Pages (from-to)417-420
Number of pages4
Issue number6
Publication statusPublished - Oct 2008



  • Cancer-related anemia
  • Erythropoiesis-stimulating agents
  • Iron supplementation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this